Lidocaine attenuates CFA‑induced inflammatory pain in rats by regulating the MAPK/ERK/NF‑κB signaling pathway

Zhang,Shuli; Li,Yan; Tu,Yingjun

doi:10.3892/etm.2021.9643

Lidocaine attenuates CFA‑induced inflammatory pain in rats by regulating the MAPK/ERK/NF‑κB signaling pathway

Authors:
- Shuli Zhang
- Yan Li
- Yingjun Tu
View Affiliations

Affiliations: Department of Pain Medicine, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang 830054, P.R. China, Department of Gynecology, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang 830054, P.R. China, Department of Orthopaedics, Yili Friendship Hospital, Yining, Xinjiang 835000, P.R. China
Published online on: January 14, 2021 https://doi.org/10.3892/etm.2021.9643
Article Number: 211
Copyright: © Zhang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Lidocaine is a commonly used local anesthetic that also confers analgesic effects, resistance to hyperalgesia and anti‑inflammatory properties. The present study aimed to explore the effects of lidocaine on complete Freund's adjuvant (CFA)‑induced inflammatory pain. In the present study, rats were subcutaneously injected with CFA to investigate the molecular mechanisms associated with lidocaine in an inflammation‑induced pain model. Firstly, CFA was subcutaneously injected into the paws of Sprague‑Dawley rats, following which lidocaine or saline and the ERK agonist recombinant human epidermal growth factor (rh‑EGF) were injected via the tail vein. Rat behavior was then assessed at 0 and 4 h, 1, 4, 7 and 14 days after CFA treatment. Proinflammatory cytokine levels in the serum were measured using ELISA. Western blotting was performed to detect the protein levels of phosphorylated (p)‑ERK1/2, ERK1/2 and NF‑κB subunits p‑p65 and p65. Reverse transcription‑quantitative PCR was used to measure the mRNA expression of ERK1/2 and p65 in rat spinal cord tissues. The results showed that injection of CFA significantly reduced the mechanical withdrawal threshold, thermal withdrawal latency and the frequency of responses to cold stimulation in rats, whilst promoting tumor necrosis factor‑α, interleukin (IL)‑1β, IL‑6 levels in addition to ERK1/2, p65 protein phosphorylation. These effects were alleviated by lidocaine treatment. Furthermore, treatment with rh‑EGF reversed the protective effects of lidocaine on inflammatory pain caused by CFA. In conclusion, lidocaine inhibits the inﬂammatory response and pain through the MAPK/ERK/NF‑κB pathway in a rat model of pain induced by CFA.

View Figures

View References

1	Swieboda P, Filip R, Prystupa A and Drozd M: Assessment of pain: Types, mechanism and treatment. Ann Agric Environ Med. 1:2–7. 2013.PubMed/NCBI
2	Grace PM, Hutchinson MR, Maier SF and Watkins LR: Pathological pain and the neuroimmune interface. Nat Rev Immunol. 14:217–231. 2014.PubMed/NCBI View Article : Google Scholar
3	Fang JQ, Du JY, Liang Y and Fang JF: Intervention of electroacupuncture on spinal p38 mapk/atf-2/vr-1 pathway in treating inflammatory pain induced by CFA in rats. Mol Pain. 9(13)2013.PubMed/NCBI View Article : Google Scholar
4	Del Giorno R, Frumento P, Varrassi G, Paladini A and Coaccioli S: Assessment of chronic pain and access to pain therapy: A cross-sectional population-based study. J Pain Res. 10:2577–2584. 2017.PubMed/NCBI View Article : Google Scholar
5	Zhang B, He XL, Ding Y and Du GH: Gaultherin, a natural salicylate derivative from gaultheria yunnanensis: Towards a better non-steroidal anti-inﬂammatory drug. Eur J Pharmacol. 530:166–171. 2006.PubMed/NCBI View Article : Google Scholar
6	Chamaraux-Tran TN and Tobias P: The amide local anesthetic lidocaine in cancer surgery-potential antimetastatic effects and preservation of immune cell function? A narrative review. Front Med (Lausanne). 4(235)2017.PubMed/NCBI View Article : Google Scholar
7	Johnson MZ, Crowley PD, Foley AG, Xue C, Connolly C, Gallagher HC and Buggy DJ: Effect of perioperative lidocaine on metastasis after sevoflurane or ketamine-xylazine anaesthesia for breast tumour resection in a murine model. Br J Anaesth. 121:76–85. 2018.PubMed/NCBI View Article : Google Scholar
8	Lauretti GR: Mechanisms of analgesia of intravenous lidocaine. Rev Bras Anestesiol. 58:280–286. 2008.PubMed/NCBI View Article : Google Scholar : (In En, Portuguese).
9	Kawamata M, Takahashi T, Kozuka Y, Nawa Y, Nishikawa K, Narimatsu E, Watanabe H and Namiki A: Experimental incision-induced pain in human skin: Effects of systemic lidocaine on flare formation and hyperalgesia. Pain. 100:77–89. 2002.PubMed/NCBI View Article : Google Scholar
10	Wang L, Wang M, Li S, Wu H, Shen Q, Zhang S, Fang L and Liu R: Nebulized lidocaine ameliorates allergic airway inflammation via downregulation of TLR2. Mol Immunol. 97:94–100. 2018.PubMed/NCBI View Article : Google Scholar
11	Chiu KM, Lu CW, Lee MY, Wang MJ, Lin TY and Wang SJ: Neuroprotective and anti-inflammatory effects of lidocaine in kainic acid-injected rats. Neuroreport. 27:501–507. 2016.PubMed/NCBI View Article : Google Scholar
12	van der Wal SEI, van den Heuvel SAS, Radema SA, van Berkum BFM, Vaneker M, Steegers MAH, Scheffer GJ and Vissers KCP: The in vitro mechanisms and in vivo efficacy of intravenous lidocaine on the neuroinflammatory response in acute and chronic pain. Eur J Pain. 20:655–674. 2016.PubMed/NCBI View Article : Google Scholar
13	Liu LM, Liang DY, Ye CG, Tu WJ and Zhu T: The UII/UT system mediates upregulation of proinﬂammatory cytokines through p38MAPK and NF-κB pathways in LPS stimulated Kupffer cells. PLoS One. 10(e0121383)2015.PubMed/NCBI View Article : Google Scholar
14	Wang HL, Xing YQ, Xu YX, Rong F, Lei WF and Zhang WH: The protective effect of lidocaine on septic rats via the inhibition of high mobility group box 1 expression and NF-κB activation. Mediators Inflamm. 2013(570370)2013.PubMed/NCBI View Article : Google Scholar
15	Nagakura Y, Okada M, Kohara A, Kiso T, Toya T, Iwai A, Wanibuchi F and Yamaguchi T: Allodynia and hyperalgesia in adjuvant-induced arthritic rats: Time course of progression and efficacy of analgesics. J Pharmacol Exp Ther. 306:490–497. 2003.PubMed/NCBI View Article : Google Scholar
16	Bai G, Ambalavanar R, Wei D and Dessem D: Downregulation of selective microRNAs in trigeminal ganglion neurons following inflammatory muscle pain. Mol Pain. 3(15)2007.PubMed/NCBI View Article : Google Scholar
17	Bayne K: Revised guide for the care and use of laboratory animals available American physiological society. Physiologist. 39:208–211. 1996.PubMed/NCBI
18	Tan SS, Liu H, Wang YZ and Zhu SS: The molecular mechanisms associated with the effects of propofol in a rat model of pain due to inflammation following injection with complete freund's adjuvant. Med Sci Monit. 25:10190–10197. 2019.PubMed/NCBI View Article : Google Scholar
19	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.PubMed/NCBI View Article : Google Scholar
20	Klein JA and Jeske DR: Estimated maximal safe dosages of tumescent lidocaine. Anesth Analg. 122:1350–1359. 2016.PubMed/NCBI View Article : Google Scholar
21	Yang X, Yang LX, Wu J, Guo ML, Zhang Y and Ma SG: Treatment of lidocaine on subacute thyroiditis via restraining inflammatory factor expression and inhibiting pyroptosis pathway. J Cell Biochem: Apr 8, 2019 (Epub ahead of print).
22	Leon-Constantin MM, Alexa-Stratulat T, Luca A, Tamba BI, Trandafir LM, Harabagiu V and Cojocaru E: The morphofunctional impact of topical lidocaine formulation in inflammatory pain-experimental study. Rom J Morphol Embryol. 60:869–874. 2019.PubMed/NCBI
23	Soto G, Naranjo González M and Calero F: Intravenous lidocaine infusion. Rev Esp Anestesiol Reanim. 65:269–274. 2018.PubMed/NCBI View Article : Google Scholar : (In En, Spanish).
24	Berk T and Silberstein SD: The use and method of action of intravenous lidocaine and its metabolite in headache disorders. Headache. 58:783–789. 2018.PubMed/NCBI View Article : Google Scholar
25	Reeves DJ and Foster AE: Continuous intravenous lidocaine infusion for the management of pain uncontrolled by opioid medications. J Pain Palliat Care Pharmacother. 31:198–203. 2017.PubMed/NCBI View Article : Google Scholar
26	Hermanns H, Hollmann MW, Stevens MF, Lirk P, Brandenburger T, Piegeler T and Werdehausen R: Molecular mechanisms of action of systemic lidocaine in acute and chronic pain: A narrative review. Br J Anaesth. 123:335–349. 2019.PubMed/NCBI View Article : Google Scholar
27	Chen LJ, Ding YB, Ma PL, Jiang SH, Li KZ, Li AZ, Li MC, Shi CX, Du J and Zhou HD: The protective effect of lidocaine on lipopolysaccharide-induced acute lung injury in rats through NF-κB and p38 MAPK signaling pathway and excessive inflammatory responses. Eur Rev Med Pharmacol Sci. 22:2099–2108. 2018.PubMed/NCBI View Article : Google Scholar
28	Caminero A, Comabella M and Montalban X: Tumor necrosis factor alpha (TNF-α), anti-TNF-α and demyelination revisited: An ongoing story. J Neuroimmunol. 234:1–6. 2011.PubMed/NCBI View Article : Google Scholar
29	Luo Y, Pang Z, Zhu Q, Cai X, Yin Y, Wang M, Zhu J, Chen J, Zeng K, Zhang C and Zhang J: Locally instilled tumor necrosis factor-α antisense oligonucleotide inhibits allergic inflammation via the induction of Tregs. J Gene Med. 14:374–383. 2012.PubMed/NCBI View Article : Google Scholar
30	Slaats J, Ten Oever J, van de Veerdonk FL and Netea MG: IL-1β/IL-6/CRP and IL-18/ferritin: Distinct inflammatory programs in infections. PLoS Pathog. 12(e1005973)2016.PubMed/NCBI View Article : Google Scholar
31	Dai T, Shi KQ, Chen G, Shen YM and Pan T: Malvidin attenuates pain and inflammation in rats with osteoarthritis by suppressing NF-κB signaling pathway. Inflamm Res. 66:1075–1084. 2017.PubMed/NCBI View Article : Google Scholar
32	Dokumaci A: Performing pain and inflammation: Rendering the invisible visible. AMA J Ethics. 19:834–838. 2017.PubMed/NCBI View Article : Google Scholar
33	Barrientos RM, Hein AM, Frank MG, Watkins LR and Maier SF: Intracisternal interleukin-1 receptor antagonist prevents postoperative cognitive decline and neuroinflammatory response in aged rats. J Neurosci. 32:14641–14648. 2012.PubMed/NCBI View Article : Google Scholar
34	Wan Y, Xu J, Ma D, Zeng Y, Cibelli M and Maze M: Postoperative impairment of cognitive function in rats: A possible role for cytokine-mediated inflammation in the hippocampus. Anesthesiology. 106:436–443. 2007.PubMed/NCBI View Article : Google Scholar
35	Yuan Y, Zhang Y, He X and Fan S: Protective effects of sinomenine on CFA-induced inflammatory pain in rats. Med Sci Monit. 24:2018–2024. 2018.PubMed/NCBI View Article : Google Scholar
36	Brown MD and Sacks DB: Compartmentalised MAPK pathways. Handb Exp Pharmacol. 186:205–235. 2008.PubMed/NCBI View Article : Google Scholar
37	Aouadi M, Binetruy B, Caron L, Le Marchand-Brustel Y and Bost F: Role of MAPKs in development and differentiation: Lessons from knockout mice. Biochimie. 88:1091–1098. 2006.PubMed/NCBI View Article : Google Scholar
38	Zhong W, Shen WF, Ning BF, Hu PF, Lin Y, Yue HY, Yin C, Hou JL, Chen YX, Zhang JP, et al: Inhibition of extracellular signal-regulated kinase 1 by adenovirus mediated small interfering RNA attenuates hepatic fibrosis in rats. Hepatology. 50:1524–1536. 2009.PubMed/NCBI View Article : Google Scholar
39	Giridharan S and Srinivasan M: Mechanisms of NF-κB p65 and strategies for therapeutic manipulation. J Inflamm Res. 11:407–419. 2018.PubMed/NCBI View Article : Google Scholar
40	Sunami Y, Leithäuser F, Gul S, Fiedler K, Güldiken N, Espenlaub S, Holzmann KH, Hipp N, Sindrilaru A, Luedde T, et al: Hepatic activation of IKK/NFκB signaling induces liver fibrosis via macrophage-mediated chronic inflammation. Hepatology. 56:1117–1128. 2012.PubMed/NCBI View Article : Google Scholar
41	Chen X, Liu C, Lu Y, Yang Z, Lv Z, Xu Q, Pan Q and Lu L: Paeoniflorin regulates macrophage activation in dimethylnitrosamine-induced liver fibrosis in rats. BMC Complement Altern Med. 12(254)2012.PubMed/NCBI View Article : Google Scholar
42	Gao Y, Xi B, Li J, Li Z, Xu J, Zhong M, Xu Q, Lian Y, Wei R, Wang L, et al: Scoparone alleviates hepatic fibrosis by inhibiting the TLR-4/NF-κB pathway. J Cell Physiol: Oct 8, 2020 (Epub ahead of print).
43	Liu CH, Hua N, Fu X, Pan YL, Li B and Li XD: Metformin regulates atrial SK2 and SK3 expression through inhibiting the PKC/ERK signaling pathway in type 2 diabetic rats. BMC Cardiovasc Disord. 18(236)2018.PubMed/NCBI View Article : Google Scholar